These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

795 related items for PubMed ID: 10636252

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness of statins in acute coronary syndromes.
    Foody JM, Nissen SE.
    Am J Cardiol; 2001 Aug 16; 88(4A):31F-5F. PubMed ID: 11520485
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB.
    Am J Med; 1998 Feb 23; 104(2A):9S-13S. PubMed ID: 9550501
    [Abstract] [Full Text] [Related]

  • 7. Relation of clinical benefit to metabolic effects in lipid-lowering therapy.
    Herd JA.
    Am J Cardiol; 1998 Sep 24; 82(6A):22M-25M. PubMed ID: 9766344
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP, Walter MF, Day CA, Jacob RF.
    Am J Cardiol; 2005 Sep 05; 96(5A):11F-23F. PubMed ID: 16126019
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R, Nissen SE, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nicholls SJ.
    Eur J Prev Cardiol; 2016 Mar 05; 23(5):474-85. PubMed ID: 25691546
    [Abstract] [Full Text] [Related]

  • 13. Lipid management with statins. The lower the better?
    Laufs U, Liao JK, Böhm M.
    Z Kardiol; 2004 Jan 05; 93(1):4-9. PubMed ID: 14740235
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S, Nagao K, Hirayama A.
    Am J Cardiovasc Drugs; 2011 Dec 01; 11(6):411-7. PubMed ID: 22149320
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Profiling risk and new therapeutic interventions: looking ahead.
    Shepherd J.
    Am J Med; 1998 Feb 23; 104(2A):19S-22S. PubMed ID: 9550503
    [Abstract] [Full Text] [Related]

  • 20. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.